Clinical-stage biopharmaceutical company developing antiviral therapies, with a focus on treatments that could provide a bridge to a functional cure for chronic hepatitis B (HBV)
Clinical-stage biopharmaceutical company developing antiviral therapies, with a focus on treatments that could provide a bridge to a functional cure for chronic hepatitis B (HBV). Its pipeline includes ATI-2173, an oral active-site polymerase inhibitor nucleotide (ASPIN), and ATI-1428 and ATI-1645, capsid assembly modulators.